EPS for OncoSec Medical Inc (ONCS) Expected At $-0.23

September 20, 2017 - By Clifton Ray

 EPS for OncoSec Medical Inc (ONCS) Expected At $ 0.23

Investors wait OncoSec Medical Inc (NASDAQ:ONCS) to report on October, 12. its quarterly earnings Wall Street analysts expect $-0.23 EPS, up $0.16 or 41.03 % from last year’s $-0.39 same quarter earnings. OncoSec Medical Inc’s Wall Street analysts see 4.55 % negative EPS growth, taking into account the $-0.22 EPS reproted in the previous quarter, It closed at $0.99 lastly. It is down 34.57% since September 20, 2016 and is downtrending. It has underperformed by 51.27% the S&P500.

OncoSec Medical Inc (NASDAQ:ONCS) Ratings Coverage

Among 4 analysts covering OncoSec Medical (NASDAQ:ONCS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. OncoSec Medical had 7 analyst reports since March 9, 2016 according to SRatingsIntel. Maxim Group maintained OncoSec Medical Inc (NASDAQ:ONCS) on Thursday, June 8 with “Buy” rating. The stock has “Buy” rating by Maxim Group on Friday, June 2. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, March 9 report. As per Monday, June 12, the company rating was maintained by H.C. Wainwright. The rating was reinitiated by Rodman & Renshaw on Thursday, July 21 with “Buy”. As per Tuesday, June 13, the company rating was maintained by Noble Financial. The rating was maintained by H.C. Wainwright on Friday, June 2 with “Buy”.

OncoSec Medical Incorporated is a biotechnology company. The company has market cap of $20.96 million. The Firm is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. It currently has negative earnings. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

More notable recent OncoSec Medical Inc (NASDAQ:ONCS) news were published by: Prnewswire.com which released: “OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of …” on September 05, 2017, also Prnewswire.com with their article: “OncoSec Medical Appoints Richard B. Slansky as Chief Financial Officer” published on June 25, 2015, Prnewswire.com published: “OncoSec to Host Third Quarter Financial Conference Call on June 1, 2017” on May 11, 2017. More interesting news about OncoSec Medical Inc (NASDAQ:ONCS) were released by: Marketwatch.com and their article: “0.995” published on May 05, 2011 as well as Prnewswire.com‘s news article titled: “OncoSec Medical’s Intratumoral Plasmid IL-12 Demonstrates Effectiveness at …” with publication date: March 21, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.